WEED, Inc.

What they do

WEED, Inc. operates as a multi-national bio-pharmaceutical and real estate holding company focused on cannabis-derived compounds for medical and industrial use. Its primary business activity is conducted through its wholly-owned subsidiary, Sangre AT, LLC, which is pursuing a Cannabis Genomic Study. The company also acquired Hempirical Genetics, LLC in 2022. As of the latest fiscal year, the company has generated no revenue.

Revenue drivers

• Cannabis Genomic Study (Sangre AT, LLC) — No revenue is derived from this study; the company states it needs to raise additional funds to continue the next steps.
• No revenue-generating operations — Annual revenue has been $0.00 for fiscal years 2020 through 2025, and quarterly revenue was $0.00 for all quarters from June 2025 through March 2026.

Recent performance

For the fiscal year 2025, the company reported net income of $-1.4M and diluted EPS of $-0.01, with operating cash flow of $-195,136. For the quarter ended March 31, 2026, the company reported zero revenue, total assets of $515,713, total liabilities of $1.4M, and shareholder equity of $-837,527. Cash and equivalents were only $1,795 as of March 31, 2026. Net losses have been reported every year from 2021 through 2025.

Strategy

Management states its long-term plan is to become a 'Seed-to-Sale' global holding company providing infrastructure, financial solutions, product development, and real estate options in the legal cannabis sector. During fiscal 2025, the company focused on asset preservation and modernization, including streamlining international operations and exploring blockchain and AI technologies in the regulated cannabis ecosystem. The company also maintains a long-term goal of building and purchasing labs, land, and 'Cultivation Centers' to consult and lease to universities and licensed dispensary owners.

Risks

• No revenue and limited cash — The company has no revenue and only $1,795 in cash as of March 31, 2026, which raises substantial doubt about its ability to continue as a going concern.
• Negative equity — Shareholder equity was $-837,527 as of March 31, 2026, indicating liabilities exceed assets.
• Dependence on future funding — To continue its Cannabis Genomic Study, the company states it needs to raise additional funds, which may not be available on acceptable terms.
• Regulatory and legal environment — The company's operations are subject to existing government regulations and changes in the legal landscape for cannabis and hemp, which could affect its ability to introduce products in the U.S. market.

Outlook

Management indicates the next steps in the Cannabis Genomic Study are pending additional funding. The company also intends to streamline international operations and explore blockchain and AI integration within the regulated cannabis ecosystem. No revenue is expected in the near term given the absence of current operations.